Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significant improvements ...
In a call hosted recently, Nasus Pharma (NYSE:NSRX) presented strong positive topline results from its Phase 2 clinical study ...
NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a ...
NS002 demonstrated significantly faster time to the critical 100 pg/mL epinephrine threshold compared to EpiPen®, with a median T100 of 1.69 ...
Zacks Small Cap Research on MSN
NSRX: NS002 phase II topline results
By John Vandermosten, CFA NYSE: NSRX Nasus (NYSE: NSRX) reported topline results from its pharmacokinetic (PK) and ...
Kallan Richardson put himself in contention to win the Legends Series by clinching the Ray Swan 8K on Sunday. Richardson, who ...
MicroRNAs (miRNAs) — approximately 21-nucleotide-long, genome-encoded RNAs — have emerged as key regulators of gene expression in eukaryotes. miRNAs represent just one class of small RNA regulators, ...
Traditionally, mechanotransduction research has studied the response of cells to applied forces. However, recent studies have shown that forces exerted through actomyosin-generated contractility can ...
Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that Company ...
Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to treat emergency medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results